86.24
0.34%
+0.29
GE HealthCare Technologies Inc stock is currently priced at $86.24, with a 24-hour trading volume of 1.75M.
It has seen a +0.34% increased in the last 24 hours and a -3.18% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $85.79 pivot point. If it approaches the $86.84 resistance level, significant changes may occur.
Previous Close:
$85.95
Open:
$85.36
24h Volume:
1.75M
Market Cap:
$39.35B
Revenue:
$19.55B
Net Income/Loss:
$1.57B
P/E Ratio:
25.00
EPS:
3.45
Net Cash Flow:
$1.71B
1W Performance:
+2.07%
1M Performance:
-3.18%
6M Performance:
+34.94%
1Y Performance:
+7.64%
GE HealthCare Technologies Inc Stock (GEHC) Company Profile
Name
GE HealthCare Technologies Inc
Sector
Industry
Phone
617 443 3400
Address
500 West Monroe Street, Chicago
GE HealthCare Technologies Inc Stock (GEHC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Initiated | HSBC Securities | Buy |
Feb-12-24 | Upgrade | UBS | Sell → Neutral |
Nov-30-23 | Initiated | Jefferies | Hold |
Nov-27-23 | Downgrade | UBS | Neutral → Sell |
Sep-19-23 | Initiated | Citigroup | Buy |
Aug-25-23 | Initiated | Argus | Buy |
Aug-16-23 | Initiated | Wells Fargo | Overweight |
Jul-31-23 | Initiated | BofA Securities | Neutral |
Jun-27-23 | Initiated | Morgan Stanley | Equal-Weight |
May-16-23 | Initiated | Oppenheimer | Outperform |
Apr-26-23 | Initiated | UBS | Neutral |
Apr-19-23 | Initiated | Piper Sandler | Overweight |
Apr-10-23 | Initiated | BTIG Research | Neutral |
Mar-13-23 | Initiated | Evercore ISI | Outperform |
Feb-17-23 | Initiated | Mizuho | Buy |
Jan-19-23 | Initiated | Redburn | Buy |
View All
GE HealthCare Technologies Inc Stock (GEHC) Latest News
Rising Demand Likely to Aid GE HealthCare's (GEHC) Q1 Earnings
Zacks Investment Research
GE HealthCare (GEHC) Is Considered a Good Investment by Brokers: Is That True?
Zacks Investment Research
GE HealthCare Technologies (GEHC) Laps the Stock Market: Here's Why
Zacks Investment Research
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes
Zacks Investment Research
Here's Why GE HealthCare Technologies (GEHC) Gained But Lagged the Market Today
Zacks Investment Research
GE HealthCare's (GEHC) Voluson to Aid Women's Health Imaging
Zacks Investment Research
GE HealthCare Technologies Inc Stock (GEHC) Financials Data
GE HealthCare Technologies Inc (GEHC) Revenue 2024
GEHC reported a revenue (TTM) of $19.55 billion for the quarter ending December 31, 2023, a +6.60% rise year-over-year.
GE HealthCare Technologies Inc (GEHC) Net Income 2024
GEHC net income (TTM) was $1.57 billion for the quarter ending December 31, 2023, a -18.12% decrease year-over-year.
GE HealthCare Technologies Inc (GEHC) Cash Flow 2024
GEHC recorded a free cash flow (TTM) of $1.71 billion for the quarter ending December 31, 2023, a -4.94% decrease year-over-year.
GE HealthCare Technologies Inc (GEHC) Earnings per Share 2024
GEHC earnings per share (TTM) was $3.02 for the quarter ending December 31, 2023, a -29.82% decline year-over-year.
GE HealthCare Technologies Inc Stock (GEHC) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
O'Neill Kevin Michael | CEO, PDx |
Jul 31 '23 |
Option Exercise |
40.40 |
13,275 |
536,310 |
37,300 |
O'Neill Kevin Michael | CEO, PDx |
Jul 31 '23 |
Sale |
77.32 |
15,609 |
1,206,949 |
24,025 |
Rott Roland | CEO, Ultrasound |
Jun 08 '23 |
Sale |
77.37 |
2,473 |
191,336 |
22,335 |
About GE HealthCare Technologies Inc
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Cap:
|
Volume (24h):